Growth Metrics

Supernus Pharmaceuticals (SUPN) Retained Earnings (2016 - 2026)

Supernus Pharmaceuticals has reported Retained Earnings over the past 15 years, most recently at -$44000.0 for Q4 2025.

  • Quarterly Retained Earnings fell 100.01% to -$44000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$44000.0 through Dec 2025, down 100.01% year-over-year, with the annual reading at -$44000.0 for FY2025, 100.01% down from the prior year.
  • Retained Earnings was -$44000.0 for Q4 2025 at Supernus Pharmaceuticals, down from $522.0 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $556.4 million in Q4 2024 and troughed at -$4.0 million in Q3 2022.
  • The 5-year median for Retained Earnings is $378.7 million (2021), against an average of $281.1 million.
  • Year-over-year, Retained Earnings surged 200215.66% in 2021 and then crashed 101.07% in 2022.
  • A 5-year view of Retained Earnings shows it stood at $379.9 million in 2021, then plummeted by 100.84% to -$3.2 million in 2022, then surged by 15133.05% to $482.6 million in 2023, then rose by 15.31% to $556.4 million in 2024, then tumbled by 100.01% to -$44000.0 in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Retained Earnings are -$44000.0 (Q4 2025), $522.0 million (Q3 2025), and -$200000.0 (Q2 2025).